Taylor Frigon Capital Management LLC Buys 11,075 Shares of DexCom, Inc. (NASDAQ:DXCM)

Taylor Frigon Capital Management LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 51.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 32,554 shares of the medical device company’s stock after purchasing an additional 11,075 shares during the quarter. Taylor Frigon Capital Management LLC’s holdings in DexCom were worth $2,182,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Canada Pension Plan Investment Board raised its holdings in DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after buying an additional 435,401 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Bellevue Group AG boosted its holdings in shares of DexCom by 33.5% during the first quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after purchasing an additional 306,604 shares during the period. Magnetar Financial LLC bought a new stake in shares of DexCom in the second quarter worth about $31,793,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of DexCom by 41.3% in the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock worth $104,282,000 after purchasing an additional 268,802 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on DXCM. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, October 12th. Stifel Nicolaus upped their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Robert W. Baird upped their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Finally, Royal Bank of Canada cut their target price on shares of DexCom from $130.00 to $120.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.73.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,824 shares of company stock worth $126,390 in the last three months. Insiders own 0.30% of the company’s stock.

DexCom Stock Up 2.3 %

Shares of NASDAQ:DXCM traded up $1.69 on Thursday, hitting $74.17. 1,850,960 shares of the company traded hands, compared to its average volume of 3,813,939. The stock has a 50 day simple moving average of $70.08 and a 200-day simple moving average of $98.87. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The company has a market cap of $29.50 billion, a PE ratio of 47.94, a PEG ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.34 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.